- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00005580
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus fludarabine in treating patients who have chronic lymphocytic leukemia or relapsed, indolent non-Hodgkin's lymphoma.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the toxic effects and maximum tolerated dose of bryostatin 1 and fludarabine in patients with symptomatic or advanced chronic lymphocytic leukemia or relapsed indolent non-Hodgkin's lymphoma.
- Monitor apoptosis, differentiation, and protein kinase C activity in leukemic lymphocytes exposed in vivo to bryostatin 1 and fludarabine.
- Observe the antitumor activity of this combination therapy in these patients.
OUTLINE: This is a dose-escalation, multicenter study. Patients are assigned to one of two treatment groups.
- Group I: Patients receive bryostatin 1 IV over 24 hours followed by fludarabine IV over 30 minutes daily on days 1-5.
- Group II: Patients receive fludarabine IV over 30 minutes daily on days 1-5 followed by bryostatin 1 IV over 24 hours.
In both groups, courses repeat every 4 weeks for patients with stable or responding disease.
Cohorts of 3-6 patients receive escalating doses of fludarabine and bryostatin 1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD for fludarabine is determined, the dose of bryostatin 1 is escalated.
PROJECTED ACCRUAL: Approximately 30-60 patients will be accrued for this study within 3 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10021
- New York Presbyterian Hospital - Cornell Campus
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19111
- Fox Chase Cancer Center
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298-0037
- Massey Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically confirmed chronic lymphocytic leukemia
- Stage I (symptomatic or with bulky lymphadenopathy)
- Stage II, III, or IV
- Prior chemotherapy allowed, including fludarabine or other purine nucleoside analog therapy OR
Histologically confirmed indolent non-Hodgkin's lymphoma
- Progressive or relapsed following chemotherapy
Includes the following histologies:
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/lymphomas
- Lymphoplasmacytoid lymphoma (Waldenstrom's)/immunocytoma
- Mantle cell lymphoma
Follicular lymphoma
- Small cell
- Mixed small and large cell
- Diffuse (predominately small cell type)
Marginal zone B-cell lymphoma
- Extranodal (MALT-type with or without monocytoid B-cells)
- Provisional subtype: nodal (with or without monocytoid B-cells)
- Provisional entity: splenic marginal zone lymphoma (with or without villous lymphocytes)
- Hairy cell leukemia
Peripheral T-cell and NK-cell neoplasms
- T-cell chronic lymphocytic leukemia/polylymphocytic leukemia
Large granular lymphocyte leukemia
- T-cell type
- NK-cell type
- Mycosis fungoides/Sezary's syndrome (cutaneous T-cell lymphoma)
- No CNS disease
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Zubrod 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Granulocyte count at least 1,000/mm3
- Platelet count at least 75,000/mm3
- Hemoglobin at least 8 g/dL
- Coombs negative
Hepatic:
- AST/ALT no greater than 2.5 times upper limit of normal
- Bilirubin no greater than 2 mg/mL
Renal:
- Creatinine clearance at least 40 mL/min
Other:
- No concurrent neurologic condition
- No other concurrent medical condition that would preclude study
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 3 months after study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent systemic immunoglobulin therapy
- No prior bone marrow or peripheral stem cell transplantation
Chemotherapy:
- See Disease Characteristics
- At least 3 weeks since prior systemic chemotherapy
Endocrine therapy:
- No concurrent systemic glucocorticoid therapy
Radiotherapy:
- Not specified
Surgery:
- Not specified
Other:
- No other concurrent anticancer therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Ingen (Open Label)
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Steven Grant, MD, Massey Cancer Center
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- B-cells kronisk lymfatisk leukemi
- stadium I kronisk lymfatisk leukemi
- återkommande vuxen diffusa små kluvna lymfom
- Waldenström makroglobulinemi
- återkommande follikulärt lymfom grad 1
- återkommande follikulärt lymfom grad 2
- återkommande lymfom i marginalzonen
- återkommande små lymfocytiska lymfom
- extranodal marginalzon B-cellslymfom i slemhinneassocierad lymfoid vävnad
- nodal marginalzon B-cells lymfom
- marginalzonens lymfom i mjälten
- återkommande mantelcellslymfom
- refraktär kronisk lymfatisk leukemi
- stadium II kronisk lymfatisk leukemi
- stadium III kronisk lymfatisk leukemi
- stadium IV kronisk lymfatisk leukemi
- återkommande kutant T-cell non-Hodgkin lymfom
- återkommande vuxen T-cellsleukemi/lymfom
- återkommande mycosis fungoides/Sezary syndrom
- refraktär hårcellsleukemi
- prolymfocytisk leukemi
- T-cell stor granulär lymfocytleukemi
Ytterligare relevanta MeSH-villkor
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Lymfatiska sjukdomar
- Immunproliferativa störningar
- Leukemi, B-cell
- Lymfom
- Leukemi
- Lymfom, icke-Hodgkin
- Leukemi, lymfocytisk, kronisk, B-cell
- Leukemi, lymfoid
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Adjuvans, immunologiska
- Fludarabin
- Fludarabinfosfat
- Bryostatin 1
Andra studie-ID-nummer
- CDR0000066433
- P30CA016059 (U.S.S. NIH-anslag/kontrakt)
- MCV-CCHR-9801-2C
- NCI-T97-0116
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på bryostatin 1
-
Cancer Research UKAvslutad
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AvslutadHuvud- och halscancerFörenta staterna
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AvslutadLymfomFörenta staterna
-
University of Colorado, DenverNational Cancer Institute (NCI)Avslutad
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AvslutadMyelodysplastiska syndrom | LeukemiFörenta staterna
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AvslutadMultipelt myelom och plasmacellsneoplasmaFörenta staterna
-
National Cancer Institute (NCI)Avslutad
-
Fundacion para la Investigacion Biomedica del Hospital...Avslutad
-
Icahn School of Medicine at Mount SinaiNational Cancer Institute (NCI)AvslutadLivmoderhalscancerFörenta staterna
-
University of GlasgowAvslutadÄggstockscancerStorbritannien